Background: Polycystic ovarian syndrome (PCOS) is a multifaceted disorder characterized by a diverse collection of symptoms that range from mild to severe disturbances in reproductive, endocrine, and metabolic functions. Objectives: To compare the effectiveness of Metformin and Pioglitazone in managing polycystic ovarian syndrome.
Methodology: This randomized, comparative, and observational study was conducted at ESI Hospital, Indiranagar, Bangalore, Karnataka, India. A total of 150 women aged 18-36 years diagnosed with PCOS participated in the study, which lasted six months. The participants were divided into two groups: Group A: Received Metformin (500 mg twice daily) and Group B: Received Pioglitazone (15 mg once daily). Each group initially consisted of 75 participants to account for possible dropouts. Key inclusion criteria were the presence of anovulation, hyperandrogenism, and polycystic ovaries.
Results: Out of the enrolled patients, 72 (96%) in Group A and 75 (100%) in Group B completed the study. Initially, all participants experienced irregular menstrual cycles. By the study’s conclusion, Group A: 31 (43%) achieved regular menstrual cycles and Group B: 46 (61%) achieved regular menstrual cycles. Conclusion: Pioglitazone proved to be a more effective treatment for PCOS compared to Metformin.